TP53 and AL amyloidosis: Addressing the question of toxicity of this combination treatment on normal cells, Prima-1 analog PRIMA-1Met shows limited cytotoxicity toward normal hematopoietic cells while decreasing multiple myeloma cell viability irrespective of p53 status [56].